Key Highlights: Implications: Qfitlia’s Indian authorization strengthens Sanofi’s haemophilia portfolio with an antithrombin-lowering approach that offers protection for haemophilia A and ...
Key Highlights: Implications: Zytorvi’s approval strengthens Dr. Reddy’s position in India’s esophageal cancer market by expanding access to first-line PD-1 immunotherapy without PD-...
Akums Gets CDSCO Nod for Colchicine The Story:Sanofi Healthcare India has acquired a 15.19% stake in Sanofi India for ₹1,068.2 crore, with the shares transferred internally from fellow promoter entity...
Key Highlights: Implications: Akums’ CDSCO/DCGI approval to manufacture colchicine 0.5 mg for cardiovascular risk reduction is a “first‑time‑in‑India” regulatory milestone that lets India’...
Key Highlights: Implications: Dr. Reddy’s has secured CDSCO approval for its abatacept biosimilar (250 mg IV) for adults with moderate‑to‑severe active rheumatoid arthritis and activ...
Key Highlights: Implications: The launch positions Eisai to capture first-mover advantage in India’s underpenetrated dementia market, where prevalence is already large and expected t...
Key Highlights: Implications: The approval broadens AstraZeneca’s trastuzumab deruxtecan franchise in India from later-line metastatic use into the earlier, potentially larger HER2-positiv...
Key Highlights: Implications: Wegovy’s new MASH indication turns semaglutide into a dual liver–weight disease asset in India, opening a large, under-treated fatty liver market (about two i...
Key Highlights: Implications: Poviztra’s new MASH label lets Emcure plug innovator semaglutide directly into India’s emerging fatty liver treatment market, riding on ESSENCE data (63% stea...
Key Highlights: Implications: This approval moves Enhertu + Perjeta into the front line of HER2‑positive metastatic breast cancer care in India, displacing taxane + tra...
